Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
INSULIN INJECTION HUMAN BIOSYNTHETIC
NOVO NORDISK CANADA INC
A10AB01
INSULIN (HUMAN)
100UNIT
SOLUTION
INSULIN INJECTION HUMAN BIOSYNTHETIC 100UNIT
INTRAMUSCULAR
3ML CARTRIDGE
Schedule D
INSULINS
Active ingredient group (AIG) number: 0123340001; AHFS:
APPROVED
2011-01-07
_Novolin_ _®_ _ge_ _ – _ _Product Monograph _ _ _ _ _ _ _ _ _ _ _ _ _ _Page 1 of 54 _ PRODUCT MONOGRAPH Schedule D NOVOLIN ® GE Insulin, Human Biosynthetic Injectable Solution/Suspension Manufacturer’s Standard Antidiabetic Agent Novo Nordisk Canada Inc. 300-2680 Skymark Avenue Mississauga, Ontario L4W 5L6 Date of Approval: March 11, 2016 Submission Control no: 190177 _ _ _Novolin_ _®_ _ge_ _ – _ _Product Monograph _ _ _ _ _ _ _ _ _ _ _ _ _ _Page 2 of 54 _ _ _ TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................. 1 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 DESCRIPTION........................................................................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 5 ADVERSE REACTIONS ........................................................................................................... 9 DRUG INTERACTIONS ......................................................................................................... 11 DOSAGE AND ADMINISTRATION ..................................................................................... 12 HYPOGLYCEMIA AND OVERDOSAGE ............................................................................. 15 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 16 STORAGE AND STABILITY ................................................................................................. 17 SPECIAL HAND Կարդացեք ամբողջական փաստաթուղթը